Last 5 Days Trading Activity
|Date||Open Price||Close Price||High||Low||Volume|
Last 5 Days Short Activity
|Date||Short Volume||Total Volume||Short Percentage||Short Indicator|
* Cover Mode
About Molecular Pharmacology (USA), Ltd. (OTC: MLPH)
Molecular Pharmacology USA Limited, MPL USA is a public, biotechnology company dedicated to the discovery and development of analgesic and anti inflammatory products based on the proprietary MPL TL tripeptofen compound. MPL TL, an oligopeptide, is a new key active ingredient that targets a different part of the pain and inflammation cascade than other analgesic/anti inflammatory drugs. It is the first significant new topical analgesic discovery in nearly years and will drive new products and opportunity in the . billion analgesia and anti inflammatory industry. Delivered through the skin, analgesic products based on MPL TL are expected to be fast acting with localized effects and minimal anticipated drug interactions or side effects .
- Jeffrey Edwards / President, CEO
- Simon Watson / CFO, Secretary
- Jeffrey Edwards /
- Simon Watson /
Current Share Structure
- Market Cap: $557,769 - 03/16/2018
- Authorized: 300,000,000 - 03/31/2008
- Issue and Outstanding: 111,553,740 - 08/13/2013
Daily Technical Chart for (OTC: MLPH)
Stay tuned for daily updates and more on (OTC: MLPH)
More to come on (OTC: MLPH)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MLPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MLPH and does not buy, sell, or trade any shares of MLPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/